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A B S T R A C T
Exosomes are cup-shaped structures, made of two lipid layers. Their size is in the range of 30–150 nm. Exosomes
are excreted to the extracellular space and function in local and systemic cellular communication. Based on their
primary origins, they can contain substantial amounts of RNA, protein, and miRNA; the horizontal transfer of
these contents signiﬁcantly determines the exosome's biological eﬀects. The endosomal origins of exosomes can
be deduced based on their surface protein markers. The use of exosomes as a diagnostic biomarker and ther-
apeutic tool, has numerous advantages because they do not pose risks such as aneuploidy and transplant re-
jection. This - overview highlights the recent ﬁndings in exosome development and current knowledge in
exosome-based therapies.
1. Introduction
Most living cells release a range of extracellular vehicles (EVs),
which are 20–200 nm in size. These EVs are categorized according to
their size, function and cellular origins, as microvesicles (MVs) (also
known as shedding vesicles or ectosomes), microparticles, prostasomes
(from the prostate gland), tolerosomes (from the intestinal epithelial
cells) and apoptotic bodies, nanovesicles and exosomes (Gomez et al.,
2018; Marote et al., 2016). The content of EVs depends on their origin.
Nonetheless, they mainly contain bioactive molecules, such as nucleic
acids, microRNA, lipids, and proteins; these molecules are delivered to
the adjacent and distant cells (Marote et al., 2016). Thus EVs can
modify the recipient cell's fate, function, and consequently modulate
the surrounding microenvironment (Fatima and Nawaz, 2015).
Microvesicles and exosomes have attracted more attention from re-
searchers than other types of EVs. Exosomes are deﬁned as derivatives
of the endosomal system, with a cup-shape morphology and a size of
30–150 nm (Lener et al., 2015). They are secreted into the extracellular
matrix through the fusion of multivesicular bodies with the cell mem-
brane. Exosomes have been detected in all body ﬂuids including blood,
cerebrospinal ﬂuid, urine, saliva, and breast milk, which makes their
evaluation less invasive and more cost-eﬀective (Yáñez-Mó et al.,
2015). Exosomes are secreted by a myriad of cell types and they are
named according to the cell type of origin. For example, vesicles se-
creted by the human prostate gland are referred to as Prostasomes,
which are found in seminal or prostatic ﬂuid (Aalberts et al., 2014).
Also, microvesicles secreted by cancer cells, are termed Oncosomes,
which contain oncogenes or oncogenic factors (Di Vizio et al., 2009).
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Tolerosomes have a vesicular structure; they carry MHC class II with
bound antigenic peptides sampled from the gut lumen (Karlsson et al.,
2001). Prominosomes are found in the luminal ﬂuid of the embryonic
neural tube and harbor the prominin-1 (CD133) stem cell marker
(Marzesco et al., 2005). Exosomes contribute to extracellular commu-
nications in several manners. First, exosomes act as a nano-delivery
system that transfers biological information speciﬁc to their progenitor
cells, resulting in their speciﬁcity (Stremersch et al., 2016b). Second,
exosomes' surface markers and their content makes them ideal bio-
markers (Müller, 2012). Third, accumulating data received from exo-
some-based therapies have indicated that Mesenchymal stem cell
(MSC)-derived exosomes are mediators of regeneration in diﬀerent or-
gans (Lai et al., 2010). Therefore, MSC-derived exosomes have been
applied in the treatment of several diseases and in wound healing (Ko
et al., 2015; Webber et al., 2015; Lou et al., 2017; Tan et al., 2014;
Shabbir et al., 2015). Finally, exosomes can present the MHC-peptide
complex and contribute to the activation of immune responses; hence,
exosomes can be applied as vaccines (Zitvogel et al., 1998b). In this
article, we review exosomes' roles and functions, their potential ther-
apeutic application in several diseases, including in wound healing, and
in anti-tumor immunotherapy. Moreover, exosome history, biogenesis,
characteristics, and puriﬁcation methods are also explained.
2. Exosome biogenesis
Exosome biogenesis begins with early endosomes. Throughout the
life cycle of eukaryotic cells, small amounts of intracellular ﬂuid are
engulfed and small intracellular bodies, called early endosomes, are
formed. Early endosomes fuse with endocytic vesicles and incorporate
their content; the resulting vesicles may have various destinations (re-
cycling, degradation, or exocytosis). Some of the early endosomes un-
dergo a series of transformations in order to convert to the late endo-
some or MVB (Multivesicular body) (30–100 nm vesicles) that bud into
the lumen of late endosomes or intraluminal vesicles (ILV) through
diﬀerent pathways (Kowal et al., 2014). (Fig. 1.A)
The best-characterized pathway that recognizes ubiquitylated pro-
teins, based on the endosomal sorting complexes required for transport
(ESCRT) (Trajkovic et al., 2008). ESCRT consists of four diﬀerent pro-
tein complexes, ESCRT 0–3 and the associated AAA ATPase Vps4
complex. The ESCRT-0 subunit is responsible for cargo clustering in an
ubiquitin-dependent manner. This subunit recruits ubiquitinated pro-
teins and clathrin to promote internalization. Prior to the formation of
intraluminal vesicles (ILVs), ESCRT-I and ESCRT-II subunits trigger the
budding process and elevate the enzymatic de-ubiquitination of cargo
proteins. The ESCRT-III subunit drives vesicle scission, and the acces-
sory proteins (especially the VPS4 ATPase) act to dissociate and recycle
the ESCRT machinery (Théry et al., 2001; Ha et al., 2016). Another
pathway that has recently been shown is the ESCRT-independent
pathway. The elimination of key ESCRT components leads to the de-
fective formation of MVBs but does not lead to their complete absence,
indicating that the ESCRT-independent mechanism exists. These pro-
cesses include certain lipids, such as lysobisphosphatidic acid (LBPA),
ceramides, tetraspanins, or proteins such as the heat shock proteins
(Stuﬀers et al., 2009). The formation of vesicles in this pathway de-
pends on the self-organization of lipid and cargo domains. Several li-
pids, such as proteolipid protein (PLP), cholesterol, phospholipase D2
(PLD2), are enriched in exosome membranes that are secreted after
ESCRT inhibition. It seems that these lipids are essential in distinct cell
types for exosome biogenesis in the ESCRT independent pathway
(Kowal et al., 2014).
3. Functions of exosomes
The analysis of exosomal protein content shows that exosomes ori-
ginating from diﬀerent sources have diﬀerent functions. At ﬁrst, exo-
somes were originally described as a means for the disposal of
redundant proteins in reticulocyte. Further studies revealed more
functions for exosomes, such as being involved in the exclusion of
harmful molecules from the cells, exchange of materials between cells,
intercellular communication, propagation of pathogens, contribution to
the immune system, antigen presentation, and etc.(Beach et al., 2014).
Exosomes can also be used as diagnostic biomarkers, as they represent
the physiological changes of the cells and tissues that they are derived
from.
3.1. Exosomes in intercellular communication
Cell-to-cell communication involves intercellular and intracellular
signals, which are transferred either by direct cell-to-cell contact or by
secreted molecules (Camussi et al., 2010). EVs have been identiﬁed as a
new means of communication because they horizontally transfer func-
tional molecules, by carrying them to the adjacent cells (Cocucci et al.,
2009).This leads to much more complex events, compared to the sig-
naling mediated by a single ligand and receptor (Waldenström and
Ronquist, 2014). Exosomes may bind to the target cell membranes, and
as a result, they can acquire new surface molecules with novel adhesion
properties. Furthermore, they can fuse with target cells to exchange
proteins in the membrane and cytosol (cellular constituents of proteins,
RNAs, and lipids) between two cell types (Franz et al., 2016; Piehl et al.,
2013).
In total, the functions of exosomes depend on the cell/tissue that
they are derived from. For instance, exosomes released by the central
nervous system provide neural cell communication (Frühbeis et al.,
2013).
3.2. Exosomes in the immune system
Exosomes act as modulators of the adaptive and innate immune
responses. They participate in antigen presentation and in the dis-
tribution of antigens with MHC I - and MHC- II molecules (Sun et al.,
2013). Exosomes can attenuate immune responses by inhibiting the
diﬀerentiation of monocytes into the dendritic cells (DCs), improving
the function of regulatory T cells, and suppressing the activity of nat-
ural killer and CD8+ cells (Liu et al., 2006). Also, Exosomes can sti-
mulate the immune system through activation of natural killer cells
(NK), B cells, and the increased survival of hematopoietic cells. Fur-
thermore, exosomes obtained from human B cells have been shown to
prompt antigen-speciﬁc MHC class I, II responses, along with other co-
stimulatory molecules expressed in DC-derived exosomes (Ohno et al.,
2013).
3.3. Exosomes in tumorigenesis
The intact membrane fragments or vesicles extracted from the ma-
lignant eﬀusions and peripheral blood circulation of ovarian cancer
patients were shown to express inherent markers to the tumor's mem-
branes. Thus, it has initially been demonstrated that tumor-derived
microvesicles contribute to tumorigenesis (Taylor et al., 1980). Cancer
cells secrete exosomes 10-folds more than normal cells which are
considered as the eﬀective method of transferring metastatic informa-
tion. The transfer of tumor-derived exosomes (TDE) content to the non-
malignant cells triggers the activation of tumor formation and meta-
static phenotype. In fact, this type of exosome has a signiﬁcant eﬀect on
many tumor-associated events, such as metastasis, migration, pro-
liferation, angiogenesis, drug resistance, and immune suppression
(Shao et al., 2016). On the other hand, tumor antigens which are pre-
sented by DC-derived exosomes, trigger the cytotoxic T cell responses,
which in turn leads to tumor rejection (Zitvogel et al., 1998a) (Fig. 1.
B).
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4. Exosomes puriﬁcation
EVs represent only a fraction of the cell's secretome, puriﬁed from a
wide spectrum of body ﬂuids and cell culture supernatants (such as T
and B-cells, dendritic cells, platelets, mast cells, epithelial cells, en-
dothelial cells, neuronal cells, and cancerous cells) (Rani et al., 2015).
Diﬀerent methods have been developed to extract exosomes; one of the
most common procedures involves a centrifugation series to remove big
debris and dead cells, followed by high-speed ultracentrifugation to
pellet exosomes. In the Ultracentrifugation method, the separation of
the exosomes is based on the density, size, and shape of the sequential
separations. One of the beneﬁts of this method is the lower costs and
reduce risks of contamination. This strategy has some disadvantages,
for example, it cannot distinguish between exosomes and other small
vesicles or large protein aggregates. Another drawback is extensive
personnel training, a need for large amounts of starting material, low
yields of exosomes, inconsistent outcomes (exosome pellets or fractions
are easy to lose), requiring the processes that are highly labor-intensive
and time-consuming (Théry et al., 2002). Another technique is based on
sucrose density gradient ultracentrifugation, which can purify exosomal
fractions and precipitations. This method presents a poor speciﬁcity
compared to size exclusion chromatography but provides a high yield of
isolated exosomes that maintain their functions. The application of
several approaches is recommended to increase the advantages and
Fig. 1. The brief description of extracellular vesicles (EVs) biogenesis and their diﬀerent size. Early endosomes are formed from plasma membrane budding and
mature into the late endosome or multivesicular bodies (MVBs) which have two diﬀerent fates. They can merge with the lysosome and be degrade or they can fuse
with the plasma membrane to release exosomes outwardly (A). Exosomes mainly contain bioactive molecules, such as proteins, lipids, and mRNAs which are
delivered to the other cells, so they can modify the recipient cell's fate (B).
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decrease the issues associated with a single technique (Farooqi et al.,
2017). Recently, the deterministic lateral displacement (DLD) pillar
array technique has been proposed to extract exosomes, allowing for
quantiﬁcation in addition to on-chip sorting (Batrakova and Kim,
2015). The Immunoaﬃnity capture-based separation technique is based
on speciﬁc interactions between the exosome membrane and the anti-
body. This method is useful for the isolation of speciﬁc exosomes and is
performed with high purity. It is an expensive method that is applicable
to cell-free samples (Batrakova and Kim, 2015). There is a distinction in
the microﬂuidic separation method based on various characteristics of
exosomes such as immunity, size, and density. High portability, high
automation and integration, and low cost are the beneﬁts of this
method. The drawbacks of this method are the lack of standardization
and large-scale clinical sample testing (Li et al., 2017).
As a way to scale up, simplify, and shorten exosome isolation,
several companies developed the total exosome isolation kits. These
allow for a simple and reliable concentration of intact exosomes from
cell culture media and a range of body ﬂuids (serum, plasma, urine,
saliva). By tying up water molecules, the reagents force less soluble
components (i.e., exosomes) out of solution, allowing them to be col-
lected after brief, low-speed centrifugation(Invitrogen, life technology).
5. Biological characterization of EVs
There are diﬀerent methods for characterizing EVs. Size and protein
markers are the most important characteristics that have been studied.
The EVs can be detected using transmission electron microscopy (TEM),
scanning electron microscopy (SEM), and nanoparticle tracking ana-
lysis (NTA)(Sokolova et al., 2011). Furthermore, EVs can be further
characterized by mass spectrometry, ﬂow cytometry, immunoblotting,
electron microscopy, and light-scattering methods. All of these techni-
ques can measure the exosomal size (30–100 nm), and they can also
determine the exosomal morphology (cup-shaped). Biochemical char-
acterization can further reveal common surface, cytoplasmic, and cy-
toskeletal proteins that are characteristic of exosomes (Kesimer et al.,
2009). The exosome's proteomic proﬁle depends on its isolation
method. The most abundant proteins in the EV subpopulation are tet-
raspanin (CD9, CD63, CD81, and CD82), MHC molecules, 14-3-3 pro-
teins, cytosolic proteins such as heat shock proteins (HSPs), the ESCRT-
3 binding protein Alix, and Tsg101(Witwer et al., 2013). It is note-
worthy to mention, that CD63 and Tsg101 have only been detected in
speciﬁc EV subgroups (Yoshioka et al., 2013); while CD9 and CD81 are
the most identiﬁed proteins in EVs (Kim et al., 2013).
6. Applications
6.1. Therapeutic potential in clinical trials
Same as general exosomes, MSC-derived exosomes carry complex
cargo, including nucleic acids, proteins, and lipids. They are involved in
multiple biochemical and cellular processes, such as communication,
immune regulation, bioenergetics, tissue regeneration, and metabolism
(Lai et al., 2012). Because of their intercellular traﬃcking, they can act
in paracrine or endocrine signaling by aﬀecting neighboring and distant
cells. Due to their potential in diagnostic applications, presence in
diﬀerent body ﬂuids, and is less invasive and cheaper than other
methods, MSC-derived exosomes are represented as ideal biomarkers
and considered as a new therapeutic strategy (Stremersch et al., 2016a).
(Fig. 2). More supplementary information is also provided in Table 1.
6.1.1. Exosomes as vaccines in anti-tumor immunotherapy
The idea of adopting EVs as an antitumor vaccine arose from a re-
port which was published almost two decades ago. It was found that
EVs contained MHC-peptide complexes are able to activate CD4 and
CD8 T cells. In immune-competent mice, tumor cell peptide-pulsed
dendritic cells induced the growing tumor rejection by activating
tumor-speciﬁc cytotoxic T cells (Zitvogel et al., 1998a). This discovery
resulted in phase I clinical trial for anti-non-small cell lung cancer
(NSCLC) in the United States and an anti-melanoma phase I clinical trial
in France (Escudier et al., 2005; Morse et al., 2005). In these trials, the
conditioned medium of monocyte-derived DCs was used to recover EVs,
then pulsed with antigenic peptides expressed by the patients’ tumors
(MAGE-A3 or A4). Due to the safety and feasibility of EV therapy, EVs
from mature DCs were used for a phase II clinical trial (NCT01159288)
of non-small cell lung cancer (Viaud et al., 2011). In another report, a
phase I clinical trial of colorectal cancer (CRC) immunotherapy was
conducted using Ascite-derived exosomes (Aex) in combination with
the granulocyte-macrophage colony-stimulating factor (GM-CSF). The
results showed that both therapies were safe and well-tolerated; how-
ever, Aex plus GM-CSF can induce a beneﬁcial tumor-speciﬁc antitumor
cytotoxic T lymphocyte (CTL) response. Since this polytherapy is safe
and feasible, it can be a new strategy in the immune therapy of ad-
vanced CRC (Dai et al., 2008). Additionally, it has been reported that
bacteria release EVs from their cell membrane. Therefore, EVs can be
used as vaccine candidates against respective organisms. Thus, exo-
somes can increase the immune response to cancer cells as eﬀective as
bacterial-derived vesicles (Acevedo et al., 2014).
6.1.2. Exosomes in wound healing
Bone marrow MSC exosomes promote the expression of various
wound healing-related growth factors, such as insulin-Like growth
factor 1(IGF1), nerve growth factor (NGF), hepatocyte growth factor
(HGF), and stromal cell-derived factor 1 (SDF1). They also activate
multiple important signaling pathways in the wound healing process
(e.g., Akt, ERK, and STAT3). Furthermore, the results of a study showed
that MSC exosomes eﬀectively increase the growth rate of wound ﬁ-
broblasts. These ﬁndings suggest that these exosomes may mediate the
wound healing process (Shabbir et al., 2015). Another important factor
in wound healing is inﬂammation; controlling this response, without
causing toxicity to the injured tissue remains challenging. The im-
munomodulatory eﬀects of MSCs assists wound repair by releasing
exosomes, which can provide a proper microenvironment through the
horizontal transfer of exosomal microRNA. For example, the transfer of
miR-21, miR-146a, and miR-181 to acceptor cells can regulate the ex-
pression of important immuno-modulators that ﬁne-tune the TLR-in-
duced NFκB signaling pathways and its downstream targets (Ti et al.,
2016). In a skin-defect mouse model, it has been showed that umbilical
cord-derived MSCs (uMSCs) can reduce myoﬁbroblast accumulation
and scar formation, which is associated with uMSC-derived exosomes
enriched with speciﬁc miRNAs (miR-21, -23a, -125b, and -145). These
miRNAs play key roles in suppressing myoﬁbroblast formation by in-
hibiting the transforming growth factor-b2/SMAD2 pathway (Fang
et al., 2016). In one study, human umbilical cord MSC-derived exo-
somes were used for the treatment of rat skin burn wounds. The en-
hanced re-epithelialization along with Cytokeratin19 (CK19), pro-
liferating cell nuclear antigen (PCNA), and collagen I overexpression
was observed. Additionally, when there was an interference in the ex-
pression of Wnt4 in hucMSC-Exosomes, their therapeutic eﬀects were
inhibited (Zhang et al., 2015). This suggested that activation of Wnt/ b-
catenin by hucMSC-exosomes plays an essential role in exosome eﬀects
especially in cell proliferation.
6.1.3. Exosomes in liver disease
It has been shown in several studies that MSC-derived exosomes, in
a multitude of animal models, have useful impacts on liver disease,
including acute liver injury (drug-induced), liver ﬁbrosis, and hepato-
cellular carcinoma (HCC) (Lou et al., 2017).
6.1.3.1. Liver ﬁbrosis. MSC-derived exosomes are involved in
ameliorating liver ﬁbrosis by inhibiting both collagen production and
epithelial-mesenchymal transition of hepatocytes. Furthermore,
umbilical cord MSC-derived exosomes reduced the surface ﬁbrous
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capsules and softened their texture, alleviated hepatic inﬂammation
and collagen deposition in ﬁbrotic liver. These exosomes also recovered
serum aspartate aminotransferase (AST) activity signiﬁcantly and
decreased collagen type I and III, transforming growth factor (TGF)-
β1 and phosphorylation Smad2 expression in a mouse model (Li et al.,
2012). MicroRNAs are one of the important factors in liver
regeneration. One study showed that exosomes containing miR-125b
can decrease hepatic ﬁbrosis by deterring the activation of Hedgehog
signaling via the suppression of Smo expression resulting in reduced
ﬁbrosis (Hyun et al., 2015).
6.1.3.2. Acute liver injury. There are few reports on the therapeutic
impact of MSC exosomes in acute liver injury. Recent research has
demonstrated that exosomes derived from the HuES9.E1 MSC cell line,
improved hepatoprotective activity in acetaminophen or H2O2-induced
hepatocyte injury in vitro. However, in the following in vivo study on a
mouse model of acute liver injury, induced by carbon tetrachloride
(CCl4), increased hepatocyte proliferation, enrichment of PCNA, and
higher cell viability were demonstrated (Tan et al., 2014). Another
study on concanavalin-A-induced hepatitis indicated that
transplantation of adipose-derived MSC (AD-MSC) exosomes can
dramatically decrease serum levels of both aspartate aminotransferase
and alanine aminotransferase as well as liver inﬂammation, liver
necrosis, and the serum levels of proinﬂammatory cytokines (Lou
et al., 2017).
6.1.3.3. Hepatocellular carcinoma (HCC). It has been recently shown
that MSCs can be recruited from the bone marrow to the tumor
microenvironment. Thus, they are considered as an appropriate
candidate for tumor therapy (Barcellos-de-Souza et al., 2016). MSC-
secreted paracrine factors delivered by EVs can contribute to tumor
progression (Webber et al., 2015). Ko et al. demonstrated that AD-MSC
exosomes suppressed the growth of hepatocellular carcinoma in a rat
model. The exosome-treated rats showed partial tumor reduction,
considerably smaller tumors, with a lower mean volume ratio, and
higher apparent diﬀusion coeﬃcient compared to the controls (Ko
et al., 2015).
6.1.4. Exosomes in cardiovascular diseases (CVDs)
Exosomes contribute to cardiovascular diseases by communicating
between cardiac ﬁbroblasts, cardiomyocytes, and endothelial cells,
through delivering biological information (Hirsch et al., 2013). Such
results have been observed by Ronquist et al. who transfected exosomes
containing mRNA from the cardiomyocyte into the ﬁbroblast cells,
which changed the gene expression (Waldenström et al., 2012). In
addition, cardiac ﬁbroblast exosomal miRNAs act as paracrine-acting
RNA molecules to induce diﬀerent eﬀects through speciﬁc gene in-
hibition. For instance, Bang et al. showed that miR-21-3p induces car-
diomyocyte hypertrophy by inhibiting sorbin, as well as other genes
(Bang et al., 2014). Therefore, several exosomal genes and miRNAs,
have already been identiﬁed in CVDs.
6.1.4.1. Heart failure. The chronic activation of the myocardial renin-
angiotensin system (RAS) induces cardiac hypertrophy and a higher
level of angiotensin II (Ang II). In one study, Lyu et al. demonstrated
that Ang II treatment can potentially increase the production of
exosomes from cardiac ﬁbroblasts. Next, exosome-mediated
upregulation of angiotensinogen, renin, Ang II receptor types 1 and 2
(AT1/2R), and downregulation of angiotensin-converting enzyme 2,
increased RAS in cardiomyocytes. These results led to elevated levels of
Ang II production in the aforementioned cells, which intensiﬁes the Ang
II-induced pathological cardiac hypertrophy (Lyu et al., 2015).
On the other hand, endothelial cell-derived exosomes containing
mir-214 act as paracrine signaling mediators. These exosomes aﬀect the
ECs function and the crosstalk between them, which can enhance an-
giogenesis by stimulating the vessel formation and suppressing the ECs
senescence (van Balkom et al., 2013). However, exosomes enriched
with other miRNAs such as miR-125a, miR-21, and miR-135b have
been found to change these miRNAs' target gene expression and pro-
mote angiogenesis in ECs (Umezu et al., 2014; Liang et al., 2016;
Thuringer et al., 2016; Liu et al., 2016).
6.1.4.2. Myocardial ischemic injury. miRNAs have also been found in
the ischemic heart. As an example, the higher amount of miR-133a and
miR-1 have been observed to be localized in injured myocardium-
derived exosomes, which can be delivered to the neighboring cells
(Kuwabara et al., 2011). Moreover, in one study by Vicencio et al., the
importance of exosome surface factors has been demonstrated. They
identiﬁed a pro-survival signaling pathway in cardiomyocytes involving
toll-like receptor (TLR4) and several kinases, leading to activation of
Fig. 2. Several therapeutic applications of exosome in various disease.
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the cardioprotective HSP27. In fact, the HSP70 in the plasma of
exosomes mediate myocardium protection through the HSP70/TLR4
axis (Vicencio et al., 2015).
6.1.5. Neurodegenerative disorders
In relation to neurodegenerative disorders, Emmanouilidou et al.
demonstrated that exosomes secrete α-synuclein, which is one of the
involved factors in Parkinson's disease pathogenesis (Emmanouilidou
et al., 2010). Furthermore, proteome studies have revealed that exo-
somes contain a variety of neurodegenerative disease related cytosolic
proteins, with regard to their intracellular origins. These exosomes
determine the involved mechanism of their release into the extra-
cellular space. Moreover, proteins and biomarkers can be extracted
from circulating exosomes and also even the probable mechanism of
neuropathologic lesion spreading can be identiﬁed (Alvarez-Erviti
et al., 2011a; Emmanouilidou et al., 2010). In one study, Alvarez-Erviti
et al. utilized immature murine dendritic cell-derived exosomes and
modiﬁed them. The ﬁnal exosomes were contained speciﬁc membrane
proteins and loaded with speciﬁc siRNA for the β-site APP cleaving
enzyme 1 (BACE1) gene which is one of the proteins responsible for
Alzheimer’s disease. After exosome intravenous injection, the exosomes
moved to the microglia, neurons, and oligodendrocytes of the mouse
brain and decreased the BACE1mRNA and protein (Alvarez-Erviti et al.,
2011b). These ﬁndings verify the potential of exosome-mediated RNAi
technology in other neurodegenerative diseases by targeting their key
mediators.
6.2. Exosomal miRNAs have both therapeutic and biomarker potentials
Exosomal miRNAs can be used as novel therapeutic treatments
against several human diseases, including cancer, virus-induced, and
parasitic diseases. A major limitation of miRNA therapy is the lack of an
eﬃcient cell-speciﬁc gene delivery system. In comparison with several
gene delivery systems, exosomes provide unique advantages. First,
exosomes can aﬀect cell function by carrying biological information
such as miRNA. They can also deliver biological information in the form
of miRNA to speciﬁc cell types, through receptor-mediated binding.
Second, exosomes have less oﬀ-target eﬀects, due to their rapid ab-
sorption by recipient cells (Mittelbrunn et al., 2011). In a serial study, a
group of researchers indicated that the transfection of miR-146b re-
duces migration, invasion, and viability of glioma cells. Moreover, miR-
146b suppresses the malignant phenotype through EGFR inhibition
(Katakowski et al., 2010). In one study, marrow stromal cell (MSC)
exosomes were used as a vehicle for the delivery of miR-146b, which
has anti-cancer eﬀects. After the intra-tumor injection of these exo-
somes to a rat tumor model, the growth of xenograft glioma was sig-
niﬁcantly reduced (Katakowski et al., 2013). Furthermore, due to the
diﬀerent exosomal miRNA proﬁle in patients and healthy individuals,
they have attracted attention for their potential in the diagnosis of the
pathological state and tumor development process (Michael et al.,
2010). Another therapeutic application is in oral potentially malignant
disorders (OPMDs). Genetically modiﬁed MSC-derived exosomes en-
riched with miR-185 diminished inﬂammatory response, inhibited cell
proliferation and angiogenesis, and induced cell apoptosis, introducing
them as a novel therapeutic approach for OPMD (Wang et al., 2019).
Therefore, the miRNA levels in a certain stage of diseases or in circu-
lating tumor-derived exosomes can be used as biomarkers. This can
clarify the pathological disease states, mechanisms involved in the pa-
thogenesis of diseases, and the potential treatment (Taylor and Gercel-
Taylor, 2008).
6.3. Exosomes as drug carriers and delivery vehicles
Exosomes can be eﬃciently used as drug delivery vehicles that can
pass through the blood-brain barrier. They are able to carry a sub-
stantial amount of therapeutic cargo to qualify as drug delivery
vehicles. It is important to deliver interfering RNAs via exosome due to
the low stability of RNAs and their fast degradation in the systemic
circulation (Ozpolat et al., 2014).
The same methodology was used to induce both gene knockdown
and reduce the viability and proliferation of ﬁbrosarcoma cells by de-
livering RAD51- and RAD52-siRNA (Shtam et al., 2013). Down-
regulation of both GAPDH (housekeeping gene) and BACE1 gene, was
observed signiﬁcantly in neurons following targeted delivery of siRNA-
enriched exosomes (Alvarez-Erviti et al., 2011b).
7. Advantages and disadvantages of exosome
As we mentioned before, exosomes contain biological information
such as DNA, protein, mRNA, and miRNA. Exosomes can deliver such
information to the recipient cells, and if they carry cell-speciﬁc factors,
they can possibly render information to the target cell. Thus, in spite of
the distance between cells, they facilitate communications between
them. Since they can be released into the body ﬂuids, they carry and
exchange information between diﬀerent organs. Furthermore, by ex-
amination of the exosomal miRNAs, the diagnosis of disease and its
involved mechanism as well as potential treatment can be obtained. of
note, exosomes are less complex and they are smaller than routine
MSCs, so their production and storage are more convenient (Katsuda
et al., 2013). While exosomes can be used as an eﬀective therapy for the
delivery of diﬀerent synthetic and biological molecules in cellular
therapy of various diseases, there are still several challenges to optimize
them. For instance, their characterization, quantiﬁcation, and potency
should be examined for clinical use. A higher amount of exosomes
would be required to fulﬁll the equivalent impact of using MSCs, ac-
cording to preclinical research so large-scale production techniques
should be created (Phinney et al., 2015). Their large-scale production
by bioreactors requires eﬃcient techniques through expansion and
immortalization. Furthermore, MSCs are heterogenic cells, thereby
their exosomes are heterogeneous that may lead to a diﬀerent eﬀect on
the target cells. In addition, MSC preconditioning with hypoxia condi-
tion, starvation, and inﬂammation to stimulate exosome release, can
alter the content of exosomes. Taken together, these data suggest that
exosome-based therapy requires a more concise insight. For this, es-
tablishing a gold standard for exosome characterization and preparing
suitable preclinical animal models to obtain safety data would be pro-
mising.
8. Conclusion
Since exosomes can produce long-term immunity and naturally
carry intercellular molecules and drugs, they have become therapeutic
carriers. Extracted exosomes that have been characterized in various
ways, can be used to treat diﬀerent types of diseases but this process is
still in clinical trial studies. In the near future, it will be expected that
their usage in medical centers will be routine due to the improvement
of the delivery methods and acquiring more knowledge about exo-
somes.
Declaration of Competing Interest
The authors declare no competing interests.
Acknowledgments
The authors acknowledge the Cellular and Molecular Research
Center of Shahrekord University of Medical Sciences and Kurdistan
University of Medical Sciences for supporting our team. This research
did not receive any speciﬁc grant from funding agencies in the public,
commercial, or not-for-proﬁt sectors not-for-proﬁt sectors.
S. Rahmati, et al. Chemistry and Physics of Lipids 226 (2020) 104836
7
References
Aalberts, M., Stout, T.A., Stoorvogel, W., 2014. Prostasomes: extracellular vesicles from
the prostate. Reproduction 147, R1–R14.
Acevedo, R., Fernandez, S., Zayas, C., Acosta, A., Sarmiento, M.E., Ferro, V.A., Rosenqvist,
E., Campa, C., Cardoso, D., Garcia, L., 2014. Bacterial outer membrane vesicles and
vaccine applications. Front. Immunol. 5, 121.
Alvarez-Erviti, L., Seow, Y., Schapira, A.H., Gardiner, C., Sargent, I.L., Wood, M.J.,
Cooper, J.M., 2011a. Lysosomal dysfunction increases exosome-mediated alpha-sy-
nuclein release and transmission. Neurobiol. Dis. 42, 360–367.
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., Wood, M.J., 2011b. Delivery of
siRNA to the mouse brain by systemic injection of targeted exosomes. Nat.
Biotechnol. 29, 341.
Bang, C., Batkai, S., Dangwal, S., Gupta, S.K., Foinquinos, A., Holzmann, A., Just, A.,
Remke, J., Zimmer, K., Zeug, A., 2014. Cardiac ﬁbroblast–derived microRNA pas-
senger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J. Clin. Invest.
124, 2136–2146.
Barcellos-De-ouza, P., Comito, G., Pons‐Segura, C., Taddei, M.L., Gori, V., Becherucci, V.,
Bambi, F., Margheri, F., Laurenzana, A., Del Rosso, M., 2016. Mesenchymal stem cells
are recruited and activated into carcinoma‐associated ﬁbroblasts by prostate cancer
microenvironment‐derived TGF‐β1. Stem Cells 34, 2536–2547.
Batrakova, E.V., Kim, M.S., 2015. Using exosomes, naturally-equipped nanocarriers, for
drug delivery. J. Control. Release 219, 396–405.
Beach, A., Zhang, H.-G., Ratajczak, M.Z., Kakar, S.S., 2014. Exosomes: an overview of
biogenesis, composition and role in ovarian cancer. J. Ovarian Res. 7, 14.
Camussi, G., Deregibus, M.C., Bruno, S., Cantaluppi, V., Biancone, L., 2010. Exosomes/
microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 78,
838–848.
Cocucci, E., Racchetti, G., Meldolesi, J., 2009. Shedding microvesicles: artefacts no more.
Trends Cell Biol. 19, 43–51.
Dai, S., Wei, D., Wu, Z., Zhou, X., Wei, X., Huang, H., Li, G., 2008. Phase I clinical trial of
autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer.
Mol. Ther. 16, 782–790.
Di Vizio, D., Kim, J., Hager, M.H., Morello, M., Yang, W., Lafargue, C.J., True, L.D., Rubin,
M.A., Adam, R.M., Beroukhim, R., 2009. Oncosome formation in prostate cancer:
association with a region of frequent chromosomal deletion in metastatic disease.
Cancer Res. 69, 5601–5609.
Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S.D., Ntzouni, M.,
Margaritis, L.H., Stefanis, L., Vekrellis, K., 2010. Cell-produced α-synuclein is se-
creted in a calcium-dependent manner by exosomes and impacts neuronal survival. J.
Neurosci. 30, 6838–6851.
Escudier, B., Dorval, T., Chaput, N., André, F., Caby, M.-P., Novault, S., Flament, C.,
Leboulaire, C., Borg, C., Amigorena, S., 2005. Vaccination of metastatic melanoma
patients with autologous dendritic cell (DC) derived-exosomes: results of theﬁrst
phase I clinical trial. J. Transl. Med. 3, 10.
Fang, S., Xu, C., Zhang, Y., Xue, C., Yang, C., Bi, H., Qian, X., Wu, M., Ji, K., Zhao, Y.,
2016. Umbilical cord‐derived mesenchymal stem cell‐derived exosomal micrornas
suppress myoﬁbroblast diﬀerentiation by inhibiting the transforming growth
factor‐β/SMAD2 pathway during wound healing. Stem Cell Transl. Med. 5,
1425–1439.
Farooqi, A.A., Desai, N.N., Qureshi, M.Z., Librelotto, D.R.N., Gasparri, M.L., Bishayee, A.,
Nabavi, S.M., Curti, V., Daglia, M., 2017. Exosome biogenesis, bioactivities and
functions as new delivery systems of natural compounds. Biotechnol. Adv.
Fatima, F., Nawaz, M., 2015. Stem cell-derived exosomes: roles in stromal remodeling,
tumor progression, and cancer immunotherapy. Chin. J. Cancer 34, 46.
Franz, C., Böing, A.N., Montag, M., Strowitzki, T., Markert, U.R., Mastenbroek, S.,
Nieuwland, R., Toth, B., 2016. Extracellular vesicles in human follicular ﬂuid do not
promote coagulation. Reprod. Biomed. Online 33, 652–655.
Frühbeis, C., Fröhlich, D., Kuo, W.P., Amphornrat, J., Thilemann, S., Saab, A.S., Kirchhoﬀ,
F., Möbius, W., Goebbels, S., Nave, K.-A., 2013. Neurotransmitter-triggered transfer
of exosomes mediates oligodendrocyte–neuron communication. PLoS Biol. 11,
e1001604.
Gomez, C., Goreham, R., Serra, J., Nann, T., Kussmann, M., 2018. Exosomics-a review of
biophysics, biology and biochemistry of exosomes with a focus on human breast milk.
Front. Genet. 9 2018-03-27.
Ha, D., Yang, N., Nadithe, V., 2016. Exosomes as therapeutic drug carriers and delivery
vehicles across biological membranes: current perspectives and future challenges.
Acta Pharm. Sin. B 6, 287–296.
Hirsch, E., Hilﬁker-Kleiner, D., Balligand, J.-L., Tarone, G., De Windt, L., Bauersachs, J.,
Ferdinandy, P., Davidson, S., Hausenloy, D.J., Schulz, R., 2013. Interaction of the
heart and its close and distant neighbours: report of the meeting of the ESC Working
Groups Myocardial Function and Cellular Biology. Cardiovasc. Res. 99, 595–599.
Hyun, J., Wang, S., Kim, J., Kim, G.J., Jung, Y., 2015. MicroRNA125b-mediated
Hedgehog signaling inﬂuences liver regeneration by chorionic plate-derived me-
senchymal stem cells. Sci. Rep.-UK 5, 14135.
Karlsson, M., Lundin, S., Dahlgren, U., Kahu, H., Pettersson, I., Telemo, E., 2001.
Tolerosomes" are produced by intestinal epithelial cells. Eur. J. Immunol. 31,
2892–2900.
Katakowski, M., Buller, B., Zheng, X., Lu, Y., Rogers, T., Osobamiro, O., Shu, W., Jiang, F.,
Chopp, M., 2013. Exosomes from marrow stromal cells expressing miR-146b inhibit
glioma growth. Cancer Lett. 335, 201–204.
Katakowski, M., Zheng, X., Jiang, F., Rogers, T., Szalad, A., Chopp, M., 2010. MiR-146b-
5p suppresses EGFR expression and reduces in vitro migration and invasion of
glioma. Cancer Invest. 28, 1024–1030.
Katsuda, T., Kosaka, N., Takeshita, F., Ochiya, T., 2013. The therapeutic potential of
mesenchymal stem cell‐derived extracellular vesicles. Proteomics 13, 1637–1653.
Kesimer, M., Scull, M., Brighton, B., Demaria, G., Burns, K., O’neal, W., Pickles, R.J.,
Sheehan, J.K., 2009. Characterization of exosome-like vesicles released from human
tracheobronchial ciliated epithelium: a possible role in innate defense. FASEB J. 23,
1858–1868.
Kim, D.-K., Kang, B., Kim, O.Y., Choi, D.-S., Lee, J., Kim, S.R., Go, G., Yoon, Y.J., Kim,
J.H., Jang, S.C., 2013. EVpedia: an integrated database of high-throughput data for
systemic analyses of extracellular vesicles. J. Extracell. Vesicles 2, 20384.
Ko, S.-F., Yip, H.-K., Zhen, Y.-Y., Lee, C.-C., Lee, C.-C., Huang, C.-C., Ng, S.-H., Lin, J.-W.,
2015. Adipose-derived mesenchymal stem cell exosomes suppress hepatocellular
carcinoma growth in a rat model: apparent diﬀusion coeﬃcient, natural killer T-cell
responses, and histopathological features. Stem Cells Int. 2015.
Kowal, J., Tkach, M., Théry, C., 2014. Biogenesis and secretion of exosomes. Curr. Opin.
Cell Biol. 29, 116–125.
Kuwabara, Y., Ono, K., Horie, T., Nishi, H., Nagao, K., Kinoshita, M., Watanabe, S., Baba,
O., Kojima, Y., Shizuta, S., 2011. Increased microRNA-1 and microRNA-133a levels in
serum of patients with cardiovascular disease indicate the existence of myocardial
damage. Circ.-Genom. Precis. ME 110, 958975.
Lai, R.C., Arslan, F., Lee, M.M., Sze, N.S.K., Choo, A., Chen, T.S., Salto-Tellez, M.,
Timmers, L., Lee, C.N., El Oakley, R.M., 2010. Exosome secreted by MSC reduces
myocardial ischemia/reperfusion injury. Stem Cell Res. 4, 214–222.
Lai, R.C., Tan, S.S., Teh, B.J., Sze, S.K., Arslan, F., De Kleijn, D.P., Choo, A., Lim, S.K.,
2012. Proteolytic potential of the MSC exosome proteome: implications for an exo-
some-mediated delivery of therapeutic proteasome. Int. J. Proteomics 2012.
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzas, E., Camussi, G., Chaput, N.,
Chatterjee, D., Court, F.A., Portillo, H.A.D., 2015. Applying extracellular vesicles
based therapeutics in clinical trials–an ISEV position paper. J. Extracell. Vesicles 4,
30087.
Li, P., Kaslan, M., Lee, S.H., Yao, J., Gao, Z., 2017. Progress in exosome isolation tech-
niques. Theranostics 7, 789.
Li, T., Yan, Y., Wang, B., Qian, H., Zhang, X., Shen, L., Wang, M., Zhou, Y., Zhu, W., Li, W.,
2012. Exosomes derived from human umbilical cord mesenchymal stem cells alle-
viate liver ﬁbrosis. Stem Cells Dev. 22, 845–854.
Liang, X., Zhang, L., Wang, S., Han, Q., Zhao, R.C., 2016. Exosomes secreted by me-
senchymal stem cells promote endothelial cell angiogenesis by transferring miR-
125a. J. Cell. Sci. 129, 2182–2189.
Liu, C., Yu, S., Zinn, K., Wang, J., Zhang, L., Jia, Y., Kappes, J.C., Barnes, S., Kimberly,
R.P., Grizzle, W.E., 2006. Murine mammary carcinoma exosomes promote tumor
growth by suppression of NK cell function. J. Immunol. 176, 1375–1385.
Liu, Y., Luo, F., Wang, B., Li, H., Xu, Y., Liu, X., Shi, L., Lu, X., Xu, W., Lu, L., 2016. STAT3-
regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic
processes of transformed human bronchial epithelial cells. Cancer Lett. 370,
125–135.
Lou, G., Chen, Z., Zheng, M., Liu, Y., 2017. Mesenchymal stem cell-derived exosomes as a
new therapeutic strategy for liver diseases. Exp. Mol. Med. 49, e346.
Lyu, L., Wang, H., Li, B., Qin, Q., Qi, L., Nagarkatti, M., Nagarkatti, P., Janicki, J.S., Wang,
X.L., Cui, T., 2015. A critical role of cardiac ﬁbroblast-derived exosomes in activating
renin angiotensin system in cardiomyocytes. J. Mol. Cell. Cardiol. 89, 268–279.
Marote, A., Teixeira, F.G., Mendes-Pinheiro, B., Salgado, A.J., 2016. MSCs-derived exo-
somes: cell-secreted nanovesicles with regenerative potential. Front. Pharmacol. 7,
231.
Marzesco, A.-M., Janich, P., Wilsch-Bräuninger, M., Dubreuil, V., Langenfeld, K., Corbeil,
D., Huttner, W.B., 2005. Release of extracellular membrane particles carrying the
stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial
cells. J. Cell. Sci. 118, 2849–2858.
Michael, A., Bajracharya, S.D., Yuen, P.S., Zhou, H., Star, R.A., Illei, G.G., Alevizos, I.,
2010. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis.
16, 34–38.
Mittelbrunn, M., Gutiérrez-Vázquez, C., Villarroya-Beltri, C., González, S., Sánchez-Cabo,
F., González, M., Bernad, A., Sánchez-Madrid, F., 2011. Unidirectional transfer of
microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat. Commun. 2,
282.
Morse, M.A., Garst, J., Osada, T., Khan, S., Hobeika, A., Clay, T.M., Valente, N.,
Shreeniwas, R., Sutton, M.A., Delcayre, A., 2005. A phase I study of dexosome im-
munotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med.
3, 9.
Müller, G., 2012. Microvesicles/exosomes as potential novel biomarkers of metabolic
diseases. Diabetes Metab. Syndr. Obes. 5, 247.
Ohno, S.-I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K.,
Mizutani, T., Ohgi, T., Ochiya, T., 2013. Systemically injected exosomes targeted to
EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21, 185–191.
Ozpolat, B., Sood, A.K., Lopez-Berestein, G., 2014. Liposomal siRNA nanocarriers for
cancer therapy. Adv. Drug Deliv. Rev. 66, 110–116.
Phinney, D.G., Di Giuseppe, M., Njah, J., Sala, E., Shiva, S., St Croix, C.M., Stolz, D.B.,
Watkins, S.C., Di, Y.P., Leikauf, G.D., 2015. Mesenchymal stem cells use extracellular
vesicles to outsource mitophagy and shuttle microRNAs. Nat. Commun. 6, 8472.
Piehl, L.L., Fischman, M.L., Hellman, U., Cisale, H., Miranda, P.V., 2013. Boar seminal
plasma exosomes: eﬀect on sperm function and protein identiﬁcation by sequencing.
Theriogenology 79, 1071–1082.
Rani, S., Ryan, A.E., Griﬃn, M.D., Ritter, T., 2015. Mesenchymal stem cell-derived ex-
tracellular vesicles: toward cell-free therapeutic applications. Mol. Ther. 23,
812–823.
Shabbir, A., Cox, A., Rodriguez-Menocal, L., Salgado, M., Badiavas, E.V., 2015.
Mesenchymal stem cell exosomes induce proliferation and migration of normal and
chronic wound ﬁbroblasts, and enhance angiogenesis in vitro. Stem Cells Dev. 24,
1635–1647.
S. Rahmati, et al. Chemistry and Physics of Lipids 226 (2020) 104836
8
Shao, Y., Shen, Y., Chen, T., Xu, F., Chen, X., Zheng, S., 2016. The functions and clinical
applications of tumor-derived exosomes. Oncotarget 7, 60736.
Shtam, T.A., Kovalev, R.A., Varfolomeeva, E.Y., Makarov, E.M., Kil, Y.V., Filatov, M.V.,
2013. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell
Commun. Signal 11, 88.
Sokolova, V., Ludwig, A.-K., Hornung, S., Rotan, O., Horn, P.A., Epple, M., Giebel, B.,
2011. Characterisation of exosomes derived from human cells by nanoparticle
tracking analysis and scanning electron microscopy. Colloids Surf. B 87, 146–150.
Stremersch, S., De Smedt, S.C., Raemdonck, K., 2016a. Therapeutic and diagnostic ap-
plications of extracellular vesicles. J. Control. Release 244, 167–183.
Stremersch, S., De Smedt, S.C., Raemdonck, K., 2016b. Therapeutic and diagnostic ap-
plications of extracellular vesicles. J. Control. Release 244, 167–183.
Stuﬀers, S., Sem Wegner, C., Stenmark, H., Brech, A., 2009. Multivesicular endosome
biogenesis in the absence of ESCRTs. Traﬃc 10, 925–937.
Sun, D., Zhuang, X., Zhang, S., Deng, Z.-B., Grizzle, W., Miller, D., Zhang, H.-G., 2013.
Exosomes are endogenous nanoparticles that can deliver biological information be-
tween cells. Adv. Drug Deliver Rev. 65, 342–347.
Tan, C.Y., Lai, R.C., Wong, W., Dan, Y.Y., Lim, S.-K., Ho, H.K., 2014. Mesenchymal stem
cell-derived exosomes promote hepatic regeneration in drug-induced liver injury
models. Stem Cell Res. Ther. 5, 76.
Taylor, D.D., Gercel-Taylor, C., 2008. MicroRNA signatures of tumor-derived exosomes as
diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110, 13–21.
Taylor, D.D., Homesley, H.D., Doellgast, G.J., 1980. Binding of speciﬁc peroxidase-la-
beled antibody to placental-type phosphatase on tumor-derived membrane frag-
ments. Cancer Res. 40, 4064–4069.
Théry, C., Boussac, M., Véron, P., Ricciardi-Castagnoli, P., Raposo, G., Garin, J.,
Amigorena, S., 2001. Proteomic analysis of dendritic cell-derived exosomes: a se-
creted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 166,
7309–7318.
Théry, C., Zitvogel, L., Amigorena, S., 2002. Exosomes: composition, biogenesis and
function. Nat. Rev. Immunol. 2, 569–579.
Thuringer, D., Jego, G., Berthenet, K., Hammann, A., Solary, E., Garrido, C., 2016. Gap
junction-mediated transfer of miR-145-5p from microvascular endothelial cells to
colon cancer cells inhibits angiogenesis. Oncotarget 7, 28160.
Ti, D., Hao, H., Fu, X., Han, W., 2016. Mesenchymal stem cells-derived exosomal
microRNAs contribute to wound inﬂammation. Sci. China Life Sci. 59, 1305–1312.
Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L., Wenzel, D., Wieland, F., Schwille, P.,
Brügger, B., Simons, M., 2008. Ceramide triggers budding of exosome vesicles into
multivesicular endosomes. Science 319, 1244–1247.
Umezu, T., Tadokoro, H., Azuma, K., Yoshizawa, S., Ohyashiki, K., Ohyashiki, J.H., 2014.
Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogen-
esis by targeting factor-inhibiting HIF-1. Blood 2014-05-576116.
Van Balkom, B.W., De Jong, O.G., Smits, M., Brummelman, J., Den Ouden, K., De Bree,
P.M., Van Eijndhoven, M.A., Pegtel, D.M., Stoorvogel, W., Würdinger, T., 2013.
Endothelial cells require miR-214 to secrete exosomes that suppress senescence and
induce angiogenesis in human and mouse endothelial cells. Blood 2013-02-478925.
Viaud, S., Ploix, S., Lapierre, V., Théry, C., Commere, P.-H., Tramalloni, D., Gorrichon, K.,
Virault-Rocroy, P., Tursz, T., Lantz, O., 2011. Updated technology to produce highly
immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of in-
terferon-γ. J Immunother. 34, 65–75.
Vicencio, J.M., Yellon, D.M., Sivaraman, V., Das, D., Boi-Doku, C., Arjun, S., Zheng, Y.,
Riquelme, J.A., Kearney, J., Sharma, V., 2015. Plasma exosomes protect the myo-
cardium from ischemia-reperfusion injury. J. Am. Coll. Cardiol. 65, 1525–1536.
Waldenström, A., Gennebäck, N., Hellman, U., Ronquist, G., 2012. Cardiomyocyte mi-
crovesicles contain DNA/RNA and convey biological messages to target cells. PLoS
One 7, e34653.
Waldenström, A., Ronquist, G., 2014. Role of exosomes in myocardial remodeling. Circ.
Res. 114, 315–324.
Wang, L., Yin, P., Wang, J., Wang, Y., Sun, Z., Zhou, Y., Guan, X., 2019. Delivery of
mesenchymal stem cells-derived extracellular vesicles with enriched miR-185 inhibits
progression of OPMD. Artif. Cell Nanomed. B 47, 2481–2491.
Webber, J., Yeung, V., Clayton, A., 2015. Extracellular vesicles as modulators of the
cancer microenvironment. Semin. Cell Dev. Biol. 27–34 Elsevier.
Witwer, K.W., Buzas, E.I., Bemis, L.T., Bora, A., Lässer, C., Lötvall, J., Nolte-‘T Hoen, E.N.,
Piper, M.G., Sivaraman, S., Skog, J., 2013. Standardization of sample collection,
isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles
2, 20360.
Yáñez-Mó, M., Siljander, P.R.-M., Andreu, Z., Bedina Zavec, A., Borràs, F.E., Buzas, E.I.,
Buzas, K., Casal, E., Cappello, F., Carvalho, J., 2015. Biological properties of extra-
cellular vesicles and their physiological functions. J. Extracell. Vesicles 4, 27066.
Yoshioka, Y., Konishi, Y., Kosaka, N., Katsuda, T., Kato, T., Ochiya, T., 2013. Comparative
marker analysis of extracellular vesicles in diﬀerent human cancer types. J. Extracell.
Vesicles 2, 20424.
Zhang, B., Wang, M., Gong, A., Zhang, X., Wu, X., Zhu, Y., Shi, H., Wu, L., Zhu, W., Qian,
H., 2015. HucMSC‐exosome mediated‐Wnt4 signaling is required for cutaneous
wound healing. Stem Cells 33, 2158–2168.
Zitvogel, L., Regnault, A., Lozier, A., Wolfers, J., Flament, C., Tenza, D., Ricciardi-
Castagnoli, P., Raposo, G., Amigorena, S., 1998a. Eradication of established murine
tumors using a novel cell-free vaccine: dendritic cell derived exosomes. Nat. Med. 4,
594–600.
Zitvogel, L., Regnault, A., Lozier, A., Wolfers, J., Flament, C., Tenza, D., Ricciardi-
Castagnoli, P., Raposo, G., Amigorena, S., 1998b. Eradication of established murine
tumors using a novel cell-free vaccine: dendritic cell derived exosomes. Nat. Med. 4,
594.
S. Rahmati, et al. Chemistry and Physics of Lipids 226 (2020) 104836
9
